BeiGene
ONC
#683
Rank
$29.06 B
Marketcap
$256.16
Share price
2.82%
Change (1 day)
77.74%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Cash on Hand

Cash on Hand as of December 2024 : $2.62 Billion USD

According to BeiGene 's latest financial reports the company has $2.62 Billion USD in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31$2.62 B-17.16%
2023-12-31$3.17 B-30.06%
2022-12-31$4.53 B-31.47%
2021-12-31$6.61 B42.29%
2020-12-31$4.65 B373.24%
2019-12-31$0.98 B-44.83%
2018-12-31$1.78 B112.71%
2017-12-31$0.83 B127.48%
2016-12-31$0.36 B266.39%
2015-12-31$0.10 B126.35%
2014-12-31$44.39 M1030.79%
2013-12-31$3.92 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
$16.39 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.43 B-83.56%๐Ÿ‡บ๐Ÿ‡ธ USA